Cixutumumab Biosimilar (IGF1R / CD221 Reference Antibody)
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer.
Product Specifications
Target
Cixutumumab Biosimilar (Anti-IGF1R / CD221 Reference Antibody)
Clonality
Monoclonal
Conjugation
Unconjugated
Field of Research
Immunology & Inflammation
Purity
>98%
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GPC16046-01 25 mg
5-Fluoro-3- (4- (4-nitrophenyl) -2-oxobut-3-enylidene) indolin-2-one
Sign In for Pricing
View Details GPC16046-02 50 mg
5-Fluoro-3- (4- (4-nitrophenyl) -2-oxobut-3-enylidene) indolin-2-one
Sign In for Pricing
View Details GPC16046-03 100 mg
5-Fluoro-3- (4- (4-nitrophenyl) -2-oxobut-3-enylidene) indolin-2-one
Sign In for Pricing
View Details 